NR2F6 modulator

Regen BioPharma's NR2F6 program is a preclinical development effort focused on modulating the Nuclear Receptor Subfamily 2 Group F Member 6 (NR2F6), an intracellular immune checkpoint. NR2F6 acts as a transcriptional repressor in T cells, limiting the production of essential cytokines such as IL-2 and IFN-gamma. By utilizing small molecule inhibitors to antagonize NR2F6, the company aims to stimulate an anti-tumor immune response in various cancers. Additionally, the program explores the potential of NR2F6 modulation to treat autoimmune disorders by recalibrating immune tolerance. This approach targets a 'next-generation' checkpoint that operates within the cell nucleus, potentially offering a complementary or alternative mechanism to existing cell-surface checkpoint inhibitors like PD-1 or CTLA-4.

Other names

NR2F6-targeting programNR-2F6-targeting programNR 2F6-targeting programNR2F6 inhibitorNR-2F6 inhibitorNR 2F6 inhibitorNR2F6 immune checkpoint modulatorNR-2F6 immune checkpoint modulatorNR 2F6 immune checkpoint modulator